Cardiac Intensive Care Unit, The Heart Institute, Cincinnati Children's Hospital Medical Center, OH, USA.
Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, OH, USA; Department of Pediatrics, University of Cincinnati, College of Medicine, OH, USA.
Clin Biochem. 2020 Jul;81:1-8. doi: 10.1016/j.clinbiochem.2020.05.012. Epub 2020 May 27.
Limited data exists to-date on the laboratory findings in children with COVID-19, warranting the conduction of this study, in which we pool the currently available literature data on the laboratory findings seen in children with mild and severe COVID-19. Following an extensive literature search, we identified 24 eligible studies, including a total of 624 pediatric cases with laboratory-confirmed COVID-19, which report data on 27 different biomarkers. We then performed a meta-analysis to calculate the pooled prevalence estimates (PPE) for these laboratory abnormalities in mild COVID-19. As data was too limited for children with severe COVID-19 to allow pooling, results were presented descriptively in a summary of findings table. Our data show an inconsistent pattern of change in the leukocyte index of mild and severe cases of COVID-19 in children. Specifically, changes in leukocyte counts were only observed in 32% of the mild pediatric cases (PPE: 13% increase, 19% decrease). In mild disease, creatine kinase-MB (CK-MB) was frequently elevated, with a PPE of 33%. In severe disease, c-reactive protein (CRP), procalcitonin (PCT), and lactate dehydrogenase (LDH) were frequently elevated. Based on data obtained from early COVID-19 studies, leukocyte indices in children appear inconsistent, differing from those reported in adults that highlight specific leukocyte trends. This brings into question the utility and reliability of such parameters in monitoring disease severity in the pediatric population. Instead, we suggest physicians to serially monitor CRP, PCT, and LDH to track the course of illness in hospitalized children. Finally, elevated CK-MB in mild pediatric COVID-19 cases is indicative of possible cardiac injury. This highlights the importance of monitoring cardiac biomarkers in hospitalized patients and the need for further investigation of markers such as cardiac troponin in future studies.
目前关于 COVID-19 患儿实验室检查结果的数据有限,因此进行了这项研究,我们汇集了目前关于轻症和重症 COVID-19 患儿实验室检查结果的文献数据。经过广泛的文献检索,我们确定了 24 项符合条件的研究,共纳入 624 例实验室确诊 COVID-19 的儿科病例,报告了 27 种不同生物标志物的数据。然后我们进行了荟萃分析,计算了轻症 COVID-19 患儿这些实验室异常的合并患病率估计值(PPE)。由于缺乏重症 COVID-19 患儿的数据,无法进行合并,因此结果以发现总结表的描述性方式呈现。我们的数据显示,儿童轻症和重症 COVID-19 患者白细胞指数的变化模式不一致。具体来说,仅在 32%的轻症儿科病例中观察到白细胞计数的变化(PPE:增加 13%,减少 19%)。在轻症疾病中,肌酸激酶同工酶-MB(CK-MB)经常升高,PPE 为 33%。在重症疾病中,C 反应蛋白(CRP)、降钙素原(PCT)和乳酸脱氢酶(LDH)经常升高。根据早期 COVID-19 研究获得的数据,儿童的白细胞指数似乎不一致,与成人报告的强调特定白细胞趋势的结果不同。这使得这些参数在监测儿科人群疾病严重程度的实用性和可靠性受到质疑。相反,我们建议医生连续监测 CRP、PCT 和 LDH,以跟踪住院儿童的疾病进程。最后,轻症儿科 COVID-19 病例中 CK-MB 升高提示可能存在心脏损伤。这强调了在住院患者中监测心脏生物标志物的重要性,以及在未来研究中进一步研究心脏肌钙蛋白等标志物的必要性。